for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shanghai Junshi Biosciences Co Ltd

1877.HK

Latest Trade

41.70HKD

Change

0.65(+1.58%)

Volume

295,200

Today's Range

40.80

 - 

41.95

52 Week Range

36.50

 - 

97.15

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
41.05
Open
40.85
Volume
295,200
3M AVG Volume
20.73
Today's High
41.95
Today's Low
40.80
52 Week High
97.15
52 Week Low
36.50
Shares Out (MIL)
910.76
Market Cap (MIL)
52,630.64
Forward P/E
-144.19
Dividend (Yield %)
--

Next Event

Q3 2021 Shanghai Junshi Biosciences Co Ltd Earnings Release

Latest Developments

More

Shanghai Junshi Biosciences Says Js019 Injection Got Acceptance Notice From NMPA

Shanghai Junshi Biosciences Says U.S. FDA Expanded Emergency Use Authorization For Etesevimab & Bamlanivimab

Coherus Biosciences And Shanghai Junshi Biosciences Announced Presentation Of Positive Interim Results From Pivotal Study "Choice-01"

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shanghai Junshi Biosciences Co Ltd

Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases . The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.

Industry

Biotechnology & Drugs

Contact Info

+86.21.22500300

http://www.junshipharma.com/

Key Stats

1.70 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2019

0.8K

2020

1.6K

2021(E)

3.8K
EPS (CNY)

2019

-0.950

2020

-2.040

2021(E)

-0.240
Price To Earnings (TTM)
--
Price To Sales (TTM)
13.81
Price To Book (MRQ)
3.87
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
10.57
LT Debt To Equity (MRQ)
4.46
Return on Investment (TTM)
-17.99
Return on Equity (TTM)
-14.47

Latest News

Latest News

Lonza licenses technology to China's Junshi for experimental COVID-19 drug

Lonza Group said on Monday that China's Junshi Biosciences has licensed the Swiss contract drug manufacturer's technology to help produce a neutralizing antibody against COVID-19.

BRIEF-Shanghai Junshi Biosciences Aims To Raise 4.8 Bln Yuan In Shanghai Star Market IPO

* SAYS IT AIMS TO RAISE 4.8 BILLION YUAN ($683.52 million) AT 55.5 YUAN PER SHARE IN ITS SHANGHAI STAR MARKET IPO Source text in Chinese: https://bit.ly/2DjlhCb ($1 = 7.0225 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Shanghai Junshi Biosciences' Shanghai IPO 3,423.63 Times Oversubscribed

* SAYS ITS INITIAL SHARE PUBLIC OFFERING IN SHANGHAI 3,423.63 TIMES OVERSUBSCRIBED Source text in Chinese: https://bit.ly/3f2rr7N Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Shanghai Junshi Biosciences Sets Pricing For Shanghai IPO

* SAYS IT AIMS TO RAISE UP TO 4.8 BILLION YUAN ($678.80 million) IN INITIAL SHANGHAI SHARE OFFERING Source text in Chinese: https://bit.ly/2YNEUL3 ($1 = 7.0713 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Shanghai Junshi Biosciences Signs Clinical Trial Collaboration & Supply Deal With Merck KGaA

* SIGNED CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK KGAA

Lilly, Junshi Biosciences plan to start human trials of COVID-19 antibody in second quarter

Shanghai Junshi Biosciences Co Ltd said on Tuesday it plans to start clinical studies to test its experimental antibody against COVID-19 in the United States and China in the second quarter of the year, with partner Eli Lilly and Co.

BRIEF-Shanghai Junshi Biosciences Co Sees Significant Growth In Rev In First Half Year Of 2020

* EXPECTS TO RECORD SIGNIFICANT GROWTH IN REVENUE IN FIRST HALF YEAR OF 2020

BRIEF-Shanghai Junshi Biosciences Says Received Supplemental NDA For Toripalimab Injection

* SHANGHAI JUNSHI BIOSCIENCES-RECEIVED ACCEPTANCE NOTICE FOR SUPPLEMENTAL NEW DRUG APPLICATION FOR TORIPALIMAB INJECTION Further company coverage:

BRIEF-Shanghai Junshi Biosciences Says Domestic Shares Will Be Delisted On Neeq From 8 May

* SHANGHAI JUNSHI BIOSCIENCES- DOMESTIC SHARES WILL BE DELISTED FROM & NO LONGER BE TRADED ON NEEQ FROM 8 MAY ONWARDS Source text for Eikon: Further company coverage:

BRIEF-Eli Lilly And Junshi Biosciences To Co-Develop Therapeutic Antibodies For Treatment Of Covid-19

* SHANGHAI JUNSHI BIOSCIENCES - CO, ELI LILLY ENTERED INTO AGREEMENT TO CO-DEVELOP THERAPEUTIC ANTIBODIES FOR POTENTIAL PREVENTION, TREATMENT OF COVID-19

BRIEF-Shanghai Junshi Biosciences Enters Agreement With Eli Lilly And Company

* ENTERED RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH ELI LILLY AND COMPANY

BRIEF-Shanghai Junshi Biosciences Got Acceptance Notice For Supplemental New Drug Application For Toripalimab Injection

* GOT ACCEPTANCE NOTICE FOR SUPPLEMENTAL NEW DRUG APPLICATION IN RESPECT OF TORIPALIMAB INJECTION FROM NMPA Source text for Eikon: Further company coverage:

BRIEF-Shanghai Junshi Biosciences Updates On Proposed A Share Offering

* SOME SENIOR MANAGEMENT & CORE EMPLOYEES ESTABLISHED COLLECTIVE ASSET MANAGEMENT PLAN TO PARTICIPATE IN ALLOTMENT

BRIEF-Shanghai Junshi Biosciences Says Application For Proposed A Share Listing Of Co Approved By Star Market Stock Listing Committee

* SHANGHAI JUNSHI BIOSCIENCES CO LTD - APPLICATION FOR PROPOSED A SHARE LISTING OF CO CONSIDERED AND APPROVED BY STAR MARKET STOCK LISTING COMMITTEE Source text for Eikon: Further company coverage:

BRIEF-Shanghai Junshi Biosciences Posts FY Loss Attributable Of RMB743.9 Mln

* LOSS FOR YEAR ATTRIBUTABLE RMB743.9 MILLION VERSUS LOSS OF RMB716.4 MILLION

BRIEF-Shanghai Junshi Biosciences Says Toripalimab In Combination With Axitinib Granted Orphan-Drug Designation By US FDA

* SHANGHAI JUNSHI BIOSCIENCES - TORIPALIMAB IN COMBINATION WITH AXITINIB FOR TREATMENT OF MUCOSAL MELANOMA GRANTED ORPHAN-DRUG DESIGNATION BY US FDA Source text for Eikon: Further company coverage:

BRIEF-Shanghai Junshi Biosciences To Jointly Develop Novel Coronavirus Neutralizing Antibody

* CO WITH INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES TO DEVELOP NOVEL CORONAVIRUS NEUTRALIZING ANTIBODY Source text for Eikon: Further company coverage:

BRIEF-Shanghai Junshi Biosciences Sees Q1 Operating Income Between Rmb150 Mln To Rmb200 Mln

* SEES Q1 OPERATING INCOME BETWEEN RMB150 MILLION TO RMB200 MILLION

BRIEF-Shanghai Junshi Biosciences Says FY Net Loss Attributable RMB747.4 Mln

* FY NET LOSS ATTRIBUTABLE RMB747.4 MILLION VERSUS LOSS OF RMB722.9 MILLION

BRIEF-Shanghai Junshi Biosciences Says SSE Approved Resumption Of Review Process On Application

* APPLICATION FOR IPO & LISTING OF SHARES ON STAR MARKET OFFICIALLY ACCEPTED BY SSE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up